134 related articles for article (PubMed ID: 9413804)
1. Different sensitivity to sodium valproate in healthy, non-tumoral and tumoral hyperprolactinemic subjects.
Sarnacchiaro F; Colao A; Merola B; Di Sarno A; Landi ML; Di Somma C; Ferone D; Tolino A; Lombardi G
J Endocrinol Invest; 1997 Oct; 20(9):513-8. PubMed ID: 9413804
[TBL] [Abstract][Full Text] [Related]
2. Basal, pulsatile, entropic, and 24-hour rhythmic features of secondary hyperprolactinemia due to functional pituitary stalk disconnection mimic tumoral (primary) hyperprolactinemia.
Veldman RG; Frölich M; Pincus SM; Veldhuis JD; Roelfsema F
J Clin Endocrinol Metab; 2001 Apr; 86(4):1562-7. PubMed ID: 11297584
[TBL] [Abstract][Full Text] [Related]
3. The effects of the gabaergic drug, sodium valproate, on prolactin secretion in normal and hyperprolactinemic subjects.
Melis GB; Paoletti AM; Mais V; Mastrapasqua NM; Strigini F; Fruzzetti F; Guarnieri G; Gambacciani M; Fioretti P
J Clin Endocrinol Metab; 1982 Mar; 54(3):485-9. PubMed ID: 6799535
[TBL] [Abstract][Full Text] [Related]
4. Catecholamines and pituitary function. 2. Prolactin response to different dopamine doses in normal cycling women and patients with prolactin-secreting pituitary tumors, both before and after endogenous catecholamine synthesis inhibition.
Nicoletti I; Filipponi P; Fedeli L; Gregorini G; Ambrosi F; Sfrappini M; Santeusanio F; Brunetti P
Horm Metab Res; 1984 Dec; 16(12):658-62. PubMed ID: 6441763
[TBL] [Abstract][Full Text] [Related]
5. Effects of nomifensine on growth hormone and prolactin secretion in normal subjects and in pathological hyperprolactinemia.
Dallabonzana D; Spelta B; Botalla L; Oppizzi G; Silvestrini F; Chiodini PG; Liuzzi A
J Clin Endocrinol Metab; 1982 Jun; 54(6):1125-8. PubMed ID: 7076795
[TBL] [Abstract][Full Text] [Related]
6. Absence of a suppressive effect of 2-hydroxyestrone on hyperprolactinemia in patients with prolactinomas before and after estradiol administration.
Lamberts SW; Oosterom R
J Clin Endocrinol Metab; 1983 Feb; 56(2):230-3. PubMed ID: 6401747
[TBL] [Abstract][Full Text] [Related]
7. Prolactin responsiveness to peptide histidine methionine-27 in normal subjects and hyperprolactinemic patients.
Muratori M; Romano C; Gambino G; Faglia G
Horm Res; 1994; 42(6):257-61. PubMed ID: 7698720
[TBL] [Abstract][Full Text] [Related]
8. Exaggerated circadian variation in basal thyrotropin (TSH) and in the dopaminergic inhibition of TSH release in pathological hyperprolactinemia: evidence against a hypothalamic dopaminergic defect.
Rodriguez-Arnao MD; Peters JR; Foord SM; Dieguez C; Edwards C; Gomez-Pan A; Hall R; Newcombe RG; Scanlon MF
J Clin Endocrinol Metab; 1983 Nov; 57(5):975-80. PubMed ID: 6619271
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological activation of the GABAergic system does not affect GH and PRL release in acromegaly.
Orio F; Iovino M; Monteleone P; Agrusta M; Steardo L; Lombardi G
Horm Metab Res; 1988 Nov; 20(11):701-4. PubMed ID: 2850985
[TBL] [Abstract][Full Text] [Related]
10. Changes in the prolactin serum isoforms secreted by a pituitary adenoma associated with therapy.
Morán C; Tena G; Fonseca ME; Ochoa R; Bermúdez JA; Zárate A
Arch Med Res; 1994; 25(1):1-3. PubMed ID: 8019107
[TBL] [Abstract][Full Text] [Related]
11. Tumoral versus non-tumoral hyperprolactinemia in children and adolescents: possible usefulness of the domperidone test.
Fideleff HL; Azaretzky M; Boquete HR; Pujol AB; Honfi M; Suárez MG; Fideleff G; Giaccio AV
J Pediatr Endocrinol Metab; 2003 Feb; 16(2):163-7. PubMed ID: 12713252
[TBL] [Abstract][Full Text] [Related]
12. Hyperprolactinemia and associated pituitary prolactinomas.
Brenner SH; Lessing JB; Quagliarello J; Weiss G
Obstet Gynecol; 1985 May; 65(5):661-4. PubMed ID: 4039046
[TBL] [Abstract][Full Text] [Related]
13. Functional characterization of hypothalamic hyperprolactinemia.
Ferrari C; Rampini P; Benco R; Caldara R; Scarduelli C; Crosignani PG
J Clin Endocrinol Metab; 1982 Nov; 55(5):897-901. PubMed ID: 6811605
[TBL] [Abstract][Full Text] [Related]
14. Verapamil acute administration: a new dynamic test in hyperprolactinemic states.
Barbaro D; Faggionato F; Pallini S; Carnesecchi C; Palla A; Bombara M; Falciani C; La Gioia A; Loni G
Metabolism; 1999 Nov; 48(11):1351-6. PubMed ID: 10582540
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological activation of gamma-aminobutyric acid-system blunts prolactin response to mechanical breast stimulation in puerperal women.
Melis GB; Fruzzetti F; Paoletti AM; Mais V; Kemeny A; Strigini F; Boldrini A; Fioretti P
J Clin Endocrinol Metab; 1984 Jan; 58(1):201-5. PubMed ID: 6417154
[TBL] [Abstract][Full Text] [Related]
16. A study of pineal-prolactin interaction: prolactin response to an acute melatonin injection in patients with hyperprolactinemia.
Lissoni P; Mainini E; Mazzi C; Cattaneo G; Barni S
J Endocrinol Invest; 1990 Feb; 13(2):85-9. PubMed ID: 2329263
[TBL] [Abstract][Full Text] [Related]
17. Pituitary enlargement with suprasellar extension in functional hyperprolactinemia due to lactotroph hyperplasia: a pseudotumoral disease.
Peillon F; Dupuy M; Li JY; Kujas M; Vincens M; Mowszowicz I; Derome P
J Clin Endocrinol Metab; 1991 Nov; 73(5):1008-15. PubMed ID: 1939514
[TBL] [Abstract][Full Text] [Related]
18. The effect of the ergoline derivative, CU 32-085, on prolactin secretion in hyperprolactinemic women.
Hesla JS; Rodman EF; Molitch ME; Goodman LA; Chang RJ
Fertil Steril; 1987 Oct; 48(4):555-9. PubMed ID: 3653414
[TBL] [Abstract][Full Text] [Related]
19. mPRs represent a novel target for PRL inhibition in experimental prolactinomas.
Camilletti MA; Abeledo-Machado A; Perez PA; Faraoni EY; De Fino F; Rulli SB; Ferraris J; Pisera D; Gutierrez S; Thomas P; Díaz-Torga G
Endocr Relat Cancer; 2019 May; 26(5):497-510. PubMed ID: 30856609
[TBL] [Abstract][Full Text] [Related]
20. [Prolactin variants in serum and amniotic fluid of women with ovulatory hyperprolactinemia].
Larrea F; Escorza A; Méndez I; Ruiz JE; Valero A; Cravioto MC
Rev Invest Clin; 1991; 43(3):245-51. PubMed ID: 1818370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
